BLOG

How Japan Regulates Adipose-Derived Stem Cell Therapy

Published 2026.10.14 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

Japan is often mentioned in discussions of regenerative medicine, and many international readers wonder what that actually means for a patient. Is stem cell therapy in Japan regulated, who checks the facilities, and what should you ask before booking a consultation? This article explains the general framework in plain language and describes how adipose-derived stem cell therapy is typically organized, so that you can prepare better questions. It is general information, not medical advice, and it cannot replace an examination by a physician.

The short answer: a legal framework, and an individual medical decision

In Japan, regenerative medicine provided to patients is handled under a dedicated legal framework, commonly referred to as the Act on the Safety of Regenerative Medicine. Under this system, a medical institution that wishes to offer a regenerative treatment prepares a provision plan, has it reviewed by a certified committee, and submits it to the Ministry of Health, Labour and Welfare. Cell culture is carried out at facilities that must also meet defined requirements. In short, offering this kind of treatment is not left entirely to individual clinics’ discretion.

That said, the existence of a framework does not tell you whether a particular treatment is appropriate for you. Whether it makes sense depends on your condition, your medical history, your goals, and your physician’s assessment. Treatments under this framework are generally provided as self-pay (non-insured) medicine, which means they are not covered by Japan’s national health insurance, and the evidence for many applications is still developing.

What adipose-derived stem cell therapy involves

Stem cells are cells that can renew themselves and differentiate into other cell types. Mesenchymal stem cells are a type of somatic stem cell found in tissues such as bone marrow and fat. Laboratory and clinical research has reported that these cells can release anti-inflammatory substances and growth factors that may support tissue repair, and studies are ongoing worldwide.

Fat tissue is a commonly used source because it can be collected through a small incision under local anesthesia, which places less burden on the body than bone marrow collection. In the approach offered by Grand Green Osaka Umekita Clinic, a very small amount of your own fat tissue is collected, the mesenchymal stem cells are cultured and expanded at a specialized facility, and the cultured cells are later returned to your body by intravenous infusion. Because the cells come from you (an autologous approach), the risk of rejection is generally considered lower than with donor-derived cells, although no medical procedure is free of risk.

How the process usually unfolds for an outpatient

Knowing the sequence helps you plan travel and time away from work. The details vary by clinic and by individual, so the following is only an overview.

Consultation and examination, during which a physician reviews your history and explains the treatment, its limits, and its risks.
Collection of a small amount of fat tissue as an outpatient procedure under local anesthesia.
Culture and expansion of the cells at a specialized facility, which takes time and therefore needs to be built into your schedule.
Intravenous infusion of the cultured cells, also on an outpatient basis, followed by observation and follow-up.

Because the culture period separates collection from infusion, international patients should ask early about how many visits are needed, how long the interval is, and whether follow-up can be arranged remotely after returning home.

Questions worth asking before you decide

A good consultation is a two-way conversation. Preparing questions in advance helps you compare clinics calmly and avoid decisions driven by marketing language. Consider asking the following.

Has the clinic submitted a provision plan for this specific treatment, and can it explain which category it falls under?
Where are the cells cultured, and how is the process managed?
What are the known risks and possible side effects, and what happens if a problem occurs after you return to your home country?
What is the total cost, including consultation, collection, culture, infusion, and follow-up, and what is excluded?
Is this treatment suitable for your condition, and what alternatives, including standard treatments, should you also consider?
What is the evidence for your particular goal, and how does the physician describe its limitations?

Be cautious about any provider that promises specific results, downplays risks, or suggests that stem cell therapy should replace the treatment your own doctor recommends. Responses to cell-based treatments differ from person to person, and outcomes cannot be predicted in advance.

Planning a consultation in Osaka as an international patient

Osaka, and the Umeda area in particular, is well connected by rail and air, which makes short stays practical for visitors and for residents of Japan alike. Grand Green Osaka Umekita Clinic provides information pages for non-Japanese speakers and accepts inquiries through its website, so you can ask about language support and scheduling before you travel. If you live in Japan, the same consultation can be arranged without any travel planning.

It is also sensible to bring your existing medical records, a list of medications, and any imaging or test results, ideally with translations or summaries in English. This lets the physician judge more accurately whether the treatment is appropriate, and in some cases whether it should be postponed or not pursued at all.

Summary: use the framework as a starting point

Japan’s regulatory framework for regenerative medicine gives patients a structured way to check how a clinic is permitted to provide cell-based treatment. It does not guarantee any particular outcome. Adipose-derived stem cell therapy at Grand Green Osaka Umekita Clinic is provided as self-pay medicine under the provision plan system, and its cost, risks, side effects, and suitability for you must be confirmed in a consultation with a physician. Review the fees, treatment flow, and risk information on the clinic’s treatment page, write down your questions, and take the time you need before deciding.

Treatment Flow Overview

1ConsultationPhysician explains risks
2Fat collectionLocal anesthesia, outpatient
3Cell cultureAt a specialized facility
4IV infusionOutpatient
5Follow-up

This diagram summarizes the article as a conceptual overview

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›